Loading...
XSHE
300289
Market cap490mUSD
Oct 09, Last price  
6.12CNY
1D
1.49%
1Q
10.47%
Jan 2017
-50.84%
IPO
-1.92%
Name

Beijing Leadman Biochemistry Co Ltd

Chart & performance

D1W1MN
XSHE:300289 chart
P/E
—
P/S
10.20
EPS
—
Div yield, %
0.17%
Shrs. gr., 5y
4.00%
Rev. gr., 5y
-10.37%
Revenues
326m
-11.86%
103,809,747143,265,563185,624,994252,083,942317,273,827343,630,223536,970,837681,675,797533,391,825575,978,025654,804,224515,143,482471,510,961564,057,983564,057,983705,976,839705,976,838461,554,623370,226,868326,306,440
Net income
0
P
26,162,27841,414,91154,398,70271,850,81998,287,089110,072,016128,281,336157,219,57769,648,57673,067,13940,471,7306,309,189-50,983,72922,419,19722,419,2010-56,271,75215,337,384-75,101,3310
CFO
29m
-53.27%
21,982,23831,262,53453,464,38829,344,91857,855,64190,446,0140177,817,69181,775,815120,965,20681,020,993124,648,403135,559,303119,058,284108,933,825134,420,51562,406,24229,163,631
Dividend
May 17, 20240.01 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Leadman Biochemistry Co.,Ltd. is a prominent entity within the People's Republic of China, specializing in the entire lifecycle – from research and development to manufacturing and distribution – of advanced in vitro diagnostic (IVD) solutions. Its product portfolio encompasses a comprehensive range of biochemical raw materials. This includes critical components like enzymes, coenzymes, antibodies, various buffers, enzyme substrates, culture media, staining reagents, and amino acids. These essential ingredients serve a diverse array of sectors, notably biotechnology, clinical diagnostics, pharmaceutical development, and chemical manufacturing. Beyond raw materials, Leadman also provides specialized biochemistry diagnostic and complementary reagents. Furthermore, the company supplies a sophisticated selection of medical instrumentation. This lineup features the EnigmaML, an automated molecular testing platform designed for both clinical laboratories and various point-of-care settings like clinics and pharmacies. Another key offering is the DiaSys InnovaStar, a compact automated POCT analyzer that delivers laboratory-grade diagnostic accuracy. Customers also benefit from the DiaSys Respons, a versatile random access benchtop analyzer; the CI1000 automatic chemiluminescence immunoassay analyzers; and the IDS-isys, an instrument engineered to boost operational performance and efficiency. Established in 1997, Beijing Leadman Biochemistry maintains its corporate headquarters in Beijing, China.

Key people

President · since 2018
Yang Cheng
Finance Director · since 2019
Lihua Zhang
Deputy General Manager, Secretary of the Board · since 2019
Lin Lin
Chairman of the Board · since 2019
Zhenbin Qian
Director · since 2019
Qian Sun
Director
Independent Director
Ruiqi Wang
Independent Director · since 2012
IPO date
Feb 16, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT